- Invitae ( NYSE: NVTA ) has partnered with contract research organization Worldwide Clinical Trials to provide use for the first time of its Explorer system , which provides access to aggregated genetic testing results.
- Data insights provided are based on based on prevalence, incidence, demographics, geography, and epidemiology for rare disease patients. Worldwide Clinical can then use this data to find patients and study locations for its sponsors.
- Because patients with rare diseases are small and often scattered around the world, historically, research into treatments for these diseases has been challenging.
- Year to date, Invitae shares are down ~83%. JR Research, a Seeking Alpha contributor, considers the company a " hyped-up story stock."
For further details see:
Invitae partners with CRO for first-time use of Explorer aggregated genetic testing results